Showing results (141-150 of 150) with videos related to
Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2019
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine CarcinomaMinglei Zhuo, Yanfang Guan, Xue Yang, et al.Theranostics|January 4, 2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTao Jiang, Liyan Jiang, Xiaorong Dong, et al.Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.The Lancet. Respiratory Medicine|February 3, 2024
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trialHua Zhong, Shengjie Sun, Jianhua Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.Cancer Cell|September 10, 2024
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancerJiachen Xu, Rui Wan, Yiran Cai, et al.Signal Transduction and Targeted Therapy|December 23, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trialJia Zhong, Kailun Fei, Lin Wu, et al.Pageof 15